Exhaled Breath Biomarkers in Lung Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01386203|
Recruitment Status : Unknown
Verified February 2012 by Sheba Medical Center.
Recruitment status was: Recruiting
First Posted : June 30, 2011
Last Update Posted : February 29, 2012
Analysis of volatile organic compounds (VOCs) is a new attractive non-invasive field in medical diagnostics. These VOCs can be detected via the exhaled breath.
Together with Prof Haick group at the Technion Inst (Israel), the investigators data shows that there is a relation between the VOCs patterns of NSCLC and control cell lines and equivalent states in exhaled breath. The investigators demonstrated that there is a clear discrimination between the lung cancer and the healthy clusters . The investigators also analyzed the headspace of NSCLC and SCLC cell lines and the investigators could discriminate significantly between SCLC versus NSCLC based on their VOCs patterns. This analysis allowed us to identify the specific VOCs consumed or omitted by cancerous cells. Therefore, a non-invasive and highly sensitive test would be extremely valuable for the classification and early screening of lung cancer and for targeted therapy. In this study, the investigators will monitor the VOC pattern of patients with lung cancer as well as high risk cohort and patients under risk/evaluation for lung cancer. Likewise the investigators will monitor pts under and after therapy. In addition, the investigators will compare teh breath signature to other biomarkers of lung cancer, like circulating tumor cells and others.
|Condition or disease|
Show Detailed Description
|Study Type :||Observational|
|Estimated Enrollment :||300 participants|
|Observational Model:||Case Control|
|Official Title:||Early Detection of Lung Cancer - Exhaled Breath Nano-Analysis|
|Study Start Date :||June 2011|
|Estimated Primary Completion Date :||May 2016|
|Estimated Study Completion Date :||May 2018|
|Lung Cancer after therapy|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01386203
|Contact: Nir Peled, MD PhDfirstname.lastname@example.org|
|Sheba Medical Center||Recruiting|
|Tel Hashomer, Israel|
|Contact: Nir Peled email@example.com|
|Principal Investigator:||Nir Peled, MD PhD FCCP||Sheba Medical Center|